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Background: The objective of this study was to evaluate whether quality of life (QoL), as measured by the SF36
and the Quality of Life Interview (QoLI), is predictive of relapse for patients with schizophrenia.
Methods: Using data from a multicenter cohort study conducted in France, Germany, and the United-Kingdom
(EuroSC), we performed Cox proportional-hazards models to estimate the associations between QoL at baseline
and the occurrence of relapse over a 24-month period, with adjustment for age; gender; positive, negative and
general psychopathology PANSS factors; functioning (GAF); medication; side-effects; and compliance measures.
Results: Our sample consisted of 1,024 patients; 540 (53%) had at least one period of relapse, and 484 (47%) had
no relapse. QoL levels were the most important features predicting relapse. We found that a higher level of QoL
predicts a lower rate of relapse at 24 months: HR = 0.82 (0.74; 0.91), p < 0.001 for the SF36-Physical Composite Score;
and HR = 0.88 (0.81; 0.96), p = 0.002 for the SF36-Mental Composite Score. These results were not confirmed using
the QoLI: HR = 0.91 (0.81; 1.01), p = 0.083. To a lesser extent, older age, better functioning, and a higher compliance
score also predict a lower rate of relapse at 24 months (HRs from 0.97 to 0.98; p < 0.05).
Conclusions: QoL, as assessed by the SF36, is an independent predictor of relapse at a 24-month follow-up in
schizophrenia. This finding may have implications for future use of the QoL in psychiatry. Moreover, our findings
may support the development and monitoring of complementary therapeutic approaches, such as ‘recovery-
oriented’ combined with traditional mental health cares to prevent relapse.
Keywords: Schizophrenia, Quality of life, Relapse, Compliance, Functioning, RecoveryBackground
Schizophrenia is a severe and chronic mental illness that
is characterized by recurrent relapses [1,2]. Relapse is
disabling and distressing for the individual with schizo-
phrenia and is associated with a progressive functional
deterioration as well as worsening treatment response and
clinical prognosis [3]. Moreover, relapse increases care-
giver burden [4] and represents a significant economic
burden on families and society [5,6]. Because the preven-
tion of relapse is a major challenge in the care of patients
with schizophrenia, numerous studies have investigated
the value of socio-demographic, clinical, and medication
factors in the prediction of relapse [1,2,5,7-9]. However,
although these reports have provided a better understand-
ing of factors that influence the course of schizophrenia,* Correspondence: laurent.boyer@ap-hm.fr
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reproduction in any medium, provided the orthese factors imperfectly predict relapse, and the relapse
rate still remains high. Other factors, such as social and
environmental factors known to influence the course of
schizophrenia [10,11], have received scant attention. A
more thorough and comprehensive understanding of
these factors is necessary. On the other hand, Quality of
Life (QoL), which is defined as a subjective evaluation em-
bedded in a cultural, social, and environmental context
[12], has gained increasing acceptance in psychiatric re-
search along with the traditional assessments of clinical
outcomes. Recent studies have shown QoL to be an inde-
pendent prognostic factor associated with clinical out-
come in various chronic diseases including oncology,
often predicting survival or occurrence of hospitalization
[13-17]. However, two studies have shown that QoL scores
added relatively little to socio-demographic, clinical, and
medication factors in the prediction of relapse in schizo-
phrenia [1,5]. Because the median time to relapsetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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estimated to occur at the end of the first year [18,19], the
relatively short follow-up period of these two studies (6 and
12 months) may have underestimated the rate of relapse.
To date, no study has assessed whether QoL provides prog-
nostic information in addition to conventional socio-demo-
graphic, clinical, and medication factors for patients with
schizophrenia after a sufficient follow-up. The objective of
this study was to evaluate whether baseline QoL, as mea-
sured by the SF36 and the QoLI, is predictive of relapse for
patients with schizophrenia over a 24-month follow-up.
Methods
Study design and sampling
The data are from the European Schizophrenia Cohort
(EuroSC) conducted in France, Germany, and the United
Kingdom (UK). A detailed description of the EuroSC has
been published previously [20]. It is a naturalistic 2-year
follow-up, from 1998 to 2000, of a cohort of patients
suffering from schizophrenia. The study was observa-
tional, as no intervention was made either by or at the
behest of the research team. The main objective of the
EuroSC was to identify and describe the types of treat-
ment and methods of care for individuals with schizo-
phrenia and to correlate these with clinical outcomes,
states of health, and quality of life. This study was con-
ducted in accordance with the Declaration of Helsinki
and the French Good Clinical Practices. The protocol of
this study was approved by the Institutional Review Board
or the Ethics Committee responsible for the participating
hospital or institution: The Amden & Islington Commu-
nity Mental Health NHS Trust Ethics Committee and The
Leicester University Committee for Research Ethics for
all UK sites, The Ethics Committee of the University of
Leipzig for Germany, and The Ethics Committee of the
University of Aix-Marseille 2 for France. Written informed
consent was obtained from each participant after the study
details had been fully explained.
In France, participants were recruited from 4 areas:
Lille (Northern France), Lyon, Clermont-Ferrand (Central
France), Marseille and Toulon (Southern France). In
Germany, the study took place in 4 areas: Leipzig and
Altenburg in the former East Germany, and the districts of
Hemer and Heilbronn in the former West Germany. In the
UK, the two centers of Islington, an inner-city area of
London, and the county of Leicestershire (excluding the
city of Leicester) were chosen. In each center, patients were
identified according to the following criteria: diagnosis of
schizophrenia according to the DSM-IV criteria [21], ages
18 to 64 years, and absence of relapse for the previous
12 months. Random sampling from these patients was used
to generate a representative sample. The sample included
1,208 patients: 287 from France, 619 from Germany, and
302 from the UK. Five interviews were completed with eachparticipant at initial assessment and after every 6 months
for the subsequent 2 years. Sample attrition resulted in
1024 (84.8%) participants taking part in the second inter-
view, 914 (75.7%) in the third, 777 (64.3%) in the fourth,
and 684 (56.7%) in the final interview.
Data collection
The following data were collected at baseline:
1. Socio-demographic information: gender, age, living
conditions, and employment status.
2. Clinical characteristics: psychotic symptoms based on
the Positive and Negative Syndrome Scale (PANSS),
which includes three different subscales (positive,
negative and general psychopathology) [22]; and
functioning based on the Global Assessment of
Functioning (GAF) scale [23].
3. Drug information: Antipsychotic medication
(first-generation antipsychotics - FGAs,
second-generation antipsychotics – SGAs); the
Simpson and Angus Scale (SAS) [24], the Barnes
Akathisia Scale (BAS) [25], and the Abnormal
Involuntary Movement Scale (AIMS) [26] were used to
assess side-effects; the Rating of Medication Influences
(ROMI) Scale was used to evaluate adherence to
treatment [27]. We only examined the responses to
Part I of the ROMI, which assesses the reasons for
taking the medication. In our analysis, however, we did
not include Part 2 of the ROMI, which assesses the
reasons why people might not take their medication.
According to Weiden et al. [27], the non-compliance
items in the ROMI apply only to patients who have not
taken their medication for at least one week for any
part of the past month; otherwise, only the compliance
items are administered. The latter situation applied to
all participants in this study.
4. QoL was assessed using 2 types of questionnaires: a
generic measure usable regardless the health status of
the individual (either healthy or with different health
conditions) - the SF36 [28]; and a measurement
specific to people with chronic mental illnesses,
tailored to a broad range of mental illnesses - the
Quality of Life Interview (QoLI) [29].
The SF36 is a generic, self-administered QoL question-
naire consisting of 36 items describing 8 dimensions:
Physical Functioning (PF); Social Functioning (SF); Role—
Physical Problems (RPP); Role—Emotional Problems
(REP); Mental Health (MH); Vitality (VIT); Bodily Pain
(BP); and General Health (GH). Two composite scores
can be calculated: the physical composite score (SF36-
PCS) and the mental composite score (SF36-MCS). Each
dimension is scored within a range from 0 (low QoL level)
to 100 (high QoL level).
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assess QoL in patients with severe mental illnesses. It
consists of 74 items describing 8 domains: Living Situation
(LS), Daily Activities and functioning (DA), Family Rela-
tionships (FR), Social Relationships (SR), Finances (F),
Work and School (WS), Legal and Safety Issues (LSI), and
Mental and Physical Health (MPH). Each domain is rated
objectively by an interviewer and subjectively by the pa-
tient reporting his/her satisfaction through an individual
structured interview. Subscale scores and an overall life
satisfaction (OLS) score are calculated, ranging from 1 to
7. Higher scores indicate a better QoL.
For the purpose of the study, only the SF36-PCS,
SF36-MCS, and QoLI-OLS were included in the analyses.
Study outcomes
Our primary measure was the time to first relapse during a
24-month period. Relapse was defined according to a
common, clinically reproducible and validated definition
[30,31]: (1) hospitalization due to worsening of psychotic
symptoms or an unequivocal worsening of psychotic symp-
toms of such magnitude that hospitalization appeared
imminent, or (2) a re-emergence of florid psychotic symp-
toms such as delusions, hallucinations, or bizarre behavior,
or (3) a thought disorder lasting seven days or more. This
information was obtained by a structured clinical interview,
centred on a checklist of criteria, conducted by a psych-
iatrist every six months. Relapse was defined relative to the
baseline characteristics of the patient. Additional rele-
vant information was obtained from medical records and
through staff interviews. This process was intended to
standardise the collection of information about relapse.
Statistical analysis
Descriptive statistics, reported as means (SD) or percen-
tages, summarized baseline characteristics by relapse
status. Characteristics of patients were compared using
Chi-squared or Fisher exact tests for categorical vari-
ables and the Student or Wilcoxon rank sum test for
continuous variables. Cox proportional hazards models
were also used for the univariate analyses to predict the
interval time to relapse. Subjects were censored from
the survival analysis at the time they discontinued the
study, i.e. at the time of last interview.
Multivariate Cox proportional-hazards models were per-
formed to estimate the Hazard Ratio (HR) and its corre-
sponding 95% confidence interval (CI) for associations
between QoL scores and the occurrence of relapse, with ad-
justment for baseline characteristics, one model including
the SF36 questionnaire (SF36 model), and one model
including the QoLI (QoLI model). The adjustment variables
relevant to the models were selected from the univariate
analysis, based on a threshold p-value ≤0.20 (age, positive,
negative and general psychopathology PANSS scores, GAFscore, medication, side-effects based on the BAS score,
compliance ROMI score). An additional variable was in-
cluded in the models owing to its socio-demographic inter-
est (gender). The proportional hazards assumption was
investigated by testing the constancy of the log hazard ratio
over time by means of log-minus-log survival plots; accor-
ding to the test, the proportional hazard assumption was
not violated. The statistical significance level was set at
p < 0.05 in a two-sided test. The SAS statistical package
(SAS System for Windows, version 9.1) was used to
perform all analyses.
Results
Of the 1,208 patients in the EuroSC, 184 patients were
excluded from the analysis because they did not have any
follow-up data (15%). A total of 1,024 patients (85%) were
then included in the present analysis. There were no stat-
istical differences between the 1,024 patients in the study
group and those 184 who were excluded in terms of age,
gender, living condition, functioning (GAF score), anti-
psychotic medication, SAS, BAS AIMS, and QoL scores at
baseline (all p-values > 0.05). On the contrary, in compari-
son to included patients, excluded patients had a slightly
higher severity of symptoms (respectively 56.5 (20.2) vs.
64.3 (24.9), p = 0.001 for the total PANSS score) and lower
compliance scores (respectively 11.0 (3.3) vs. 11.5 (3.1),
p = 0.043 for the ROMI compliance score).
Baseline characteristics of patients with relapse
and no relapse
The baseline characteristics of the patients with relapse
and no relapse are reported in Table 1. Five hundred and
forty patients (53%) had at least one period of relapse, and
484 (47%) had no relapse. Patients with relapse were sig-
nificantly younger than patients with no relapse, but no
significant difference was found for gender and living
conditions. Patients with relapse also had higher levels of
severity (positive, negative, and general psychopathology
PANSS factors) and a lower level of functioning. The pro-
portion of patients receiving SGAs was significantly higher
in patients with relapse than in patients with no relapse.
Side effects as assessed with the AIMS, BAS, and SAS and
compliance as assessed with the ROMI did not differ sig-
nificantly between the two groups. Concerning QoL scores,
patients with relapse reported lower QoL levels than
patients with no relapse for the SF36-PCS, SF36-MCS, and
QoLI-OLS.
Predictors of relapse in the Cox’s proportional hazard
models
In the univariate Cox’s proportional hazard models ana-
lysis (Table 1), relapse was significantly predicted by
older age, higher level of severity, lower level of func-
tioning, SGAs, lower compliance and lower QoL level.
Table 1 Characteristics of the patients according to relapse status and univariate Cox proportional-hazards
models: Crude Hazard Ratio (HR) and its corresponding 95% confidence interval (95% CI)
Relapse
Yes (N = 540) No (N = 484)
M (SD) 1 M (SD) p-value Crude HR 95% CI p-value
Socio-demographic characteristics
Age 40.3 (10.1) 42. 0 (11.6) p = 0.013 0.99 (0.98;0.99) p = 0.004
Gender (Male), N (%)2 62.1 61.2 p = 0.773 0.97 (0.82;1.16) p = 0.762
Living alone, N (%) 33.5 34.5 p = 0.740 0.97 (0.81;1.16) p = 0.754
Unemployed, N (%) 56.9 35.7 P = 0.240 0.79 (0.53;1.15) p = 0.237
Severity of symptoms: PANSS3
Positive PANSS score 12.7 (5.7) 11.7 (5.1) p = 0.003 1.03 (1.01;1.04) p = 0.001
Negative PANSS score 16.1 (7.3) 14.6 (7.5) p = 0.002 1.02 (1.01;1.03) p = 0.001
General Psychopathology PANSS score 29.7 (10.2) 27.7 (10.1) P = 0.001 1.02 (1.01;1.02) p < 0.001
Functioning
GAF4 48.5 (15.6) 55.0 (15.9) p < 0.001 0.98 (0.98;0.99) p < 0.001
Side Effects
BAS5 1.3 (3.0) 1.1 (2.7) p = 0.192 1.02 (0.99;1.04) p = 0.147
AIMS6 3.0 (6.9) 2.5 (5.6) p = 0.228 1.01 (0.99;1.02) p = 0.328
SAS7 3.5 (8.2) 3.5 (7.7) p = 0.963 1.00 (0.99;1.011) p = 0.990
Medication
Second-generation antipsychotics (Yes), N (%) 45.6 38.9 p = 0.034 1.26 (1.06;1.49) p = 0.009
Attitude towards medication: ROMI8
ROMI compliance score 10.8 (3.5) 11.1 (3.1) p = 0.223 0.97 (0.95;0.99) p = 0.035
Quality of life
SF36 - Physical Composite Score * 47.2 (9.8) 49.1 (8.7) p = 0.001 0.83 (0.76;0.91) p < 0.001
SF36 - Mental Composite Score ** 40.3 (11.8) 43.7 (11.0) p < 0.001 0.84 (0.78;0.91) p < 0.001
QoLI - OLS score*** 4.7 (0.9) 4.8 (0.8) p = 0.006 0.86 (0.78;0.95) p = 0.003
1 Mean (Standard Deviation); 2 Effective (Percentage); 3 Positive and Negative Syndrome Scale; 4Global Assessment Functioning; 5Barnes Akathisia score;
6Abnormal Involuntary Movement Score; 7Simpson-Angus score; 8Rating of Medication Influences Scale.
* HR for the SF36 - Physical Composite Score should be interpreted this way, “an increase of 10 points on the Physical Composite Score multiplied by 0.83 the
instantaneous risk of relapse at 24 months”;
** HR for the SF36 - Mental Composite Score should be interpreted this way, “an increase of 10 points on the Mental Composite Score multiplied by 0.84 the
instantaneous risk of relapse at 24 months”;
*** HR for the QoLI - OLS score should be interpreted this way, “an increase of 1 point on the QoLI score multiplied by 0.86 the instantaneous risk of relapse at 24 months”.
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lapse during the 24 months of follow-up on the basis of
the multivariate Cox analyses are reported in Table 2. In
the SF36 model, QoL levels were the most important
features predicting relapse. A higher level of QoL pre-
dicts a lower rate of relapse at 24 months for both the
SF36-PCS and -MCS. To a lesser extent, older age, better
functioning, and higher compliance score also predict a
lower rate of relapse at 24 months. On the contrary, the
severity of symptoms and second-generation antipsychotics
did not significantly predict relapse. In the QoLI model,
only older age and better functioning predict a lower rate
of relapse.
Discussion
Using data from the observational EuroSC cohort, we
examined the predictive value of QoL with respect torelapse. Our study examined 1,024 patients with schizo-
phrenia; controlled for important socio-demographic,
clinical, and medication factors; and has attempted to
overcome the limitations of past studies by using a large
sample size and a 24-month follow-up, which enables a
more complete analysis of full relapse. The findings pro-
vide evidence in support of a relationship between QoL
scores and relapse in this patient population.
QoL, as assessed by a generic instrument (SF36), is an
independent predictor of relapse in schizophrenia. This
finding is consistent with a 12-month follow-up study
using the SF36, in which a higher level of QoL predicted
a moderately lower rate of relapse at 12 months (OR =
0.98 for both the Physical and Mental Composite Scores)
[1]. Surprisingly, this relationship was not confirmed in
our study using the QoLI, which only presented a trend
(p = 0.083). Again, this finding is consistent with a
Table 2 Factors associated with relapse during the 24 months of follow-up in the multivariate Cox proportional-
hazards models: Adjusted Hazard Ratio (HR) and its corresponding 95% confidence interval (95% CI)
SF-36 Model QoLI Model
HR 95% IC p-value HR 95% IC p-value
Quality of life
SF36 - Physical Composite Score * 0.82 (0.74;0.91) p < 0.001 - - -
SF36 - Mental Composite Score ** 0.88 (0.81;0.96) p = 0.002 - - -
QoLI - OLS score*** - - - 0.91 (0.81;1.01) p = 0.083
Socio-demographic characteristics
Age 0.98 (0.98;0.99) p = 0.001 0.98 (0.98;0.99) p < 0.001
Gender (Male) 1.06 (0.88;1.30) p = 0.532 1.12 (0.93;1.34) p = 0.249
Severity of symptoms: PANSS1
Positive PANSS score 0.99 (0.97;1.02) p = 0.514 0.99 (0.97;1.02) p = 0.560
Negative PANSS score 1.01 (0.99;1.03) p = 0.248 1.00 (0.98;1.02) p = 0.969
General Psychopathology PANSS score 0.99 (0.97;1.01) p = 0.419 1.00 (0.98;1.02) p = 0.937
Functioning
GAF2 0.98 (0.97;0.99) p < 0.001 0.98 (0.97;0.99) p < 0.001
Side Effects
BAS3 0.99 (0.95;1.02) p = 0.497 1.00 (0.97;1.03) p = 0.844
Medication
Second-generation antipsychotics (Yes) 1.07 (0.88;1.29) p = 0.508 1.13 (0.94;1.36) p = 0.195
Attitude towards medication: ROMI4
ROMI compliance score 0.97 (0.94;0.99) p = 0.041 0.97 (0.95;1.00) p = 0.063
1 Positive and Negative Syndrome Scale; 2Global Assessment Functioning; 5Barnes Akathisia score; 4Rating of Medication Influences Scale.
* HR for the SF36 - Physical Composite Score should be interpreted this way, “an increase of 10 points on the Physical Composite Score multiplied by 0.82 the
instantaneous risk of relapse at 24 months”;
** HR for the SF36 - Mental Composite Score should be interpreted this way, “an increase of 10 points on the Mental Composite Score multiplied by 0.88 the
instantaneous risk of relapse at 24 months”;
*** HR for the QoLI - OLS score should be interpreted this way, “an increase of 1 point on the QoLI score multiplied by 0.91 the instantaneous risk of relapse at 24 months”.
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relapsed patients appeared to experience a lower QoL
than non-relapsed patients at baseline, but the differ-
ences were not statistically significant [5]. The fact that a
generic instrument like the SF36 better predicts relapse
than a specific instrument like QoLI may appear para-
doxical. The use of QoL-specific instruments is generally
recommended in schizophrenia because they identify the
specific needs of patients and are more sensitive to
change and treatment/intervention effects than are gen-
eric instruments [32]. However, the QoLI is designed to
encompass a broad range of mental illnesses, not specif-
ically schizophrenia. According to Cramer et al. [32], the
QoLI showed less sensitivity to change and treatment
effect than did schizophrenia specific QoL instruments.
A previous study has also shown that a better agreement
was observed between the SF36 and schizophrenia spe-
cific QoL instruments than with the QoLI and that the
SF-36 was more strongly correlated with clinical status
than the QoLI [33].
An important finding in our study concerns the SF36-
PCS, which was a stronger relapse predictor compared
to the SF36-MCS. This finding confirms the need for
clinicians to increase their attention on the physicalhealth of patients with schizophrenia [34]. Although
most patients view their physical health as a high prior-
ity, many clinicians consider their primary function to
be the management of mental and psychological health
[35]. The subjective physical well-being of patients with
schizophrenia should thus be considered by clinicians as
an important predictor of relapse, in the same way that
psychological aspects are considered.
In our study, unlike previous studies [5,7,19,36], a
more severe symptomatology was not associated with
relapse, and other factors such as functioning or compli-
ance were only moderately associated with relapse. One
possible explanation for this discrepancy might be that
QoL, which was not taken into account as a potential
predictor in previous studies, may have a confounding
influence on the relationship between traditional predic-
tors and relapse. On the other hand, the exclusion of
more severe and less compliant patients (15% of the
cohort) may have also attenuated the predictor strength
of symptomatology and compliance. Beyond these ex-
planations, it is interesting to note that, although the
predictive value of the different factors was moderate in
our study, QoL was a stronger predictor than clinical
information.
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the recovery process. The concept of recovery is broadly
organised into 2 types: clinical objective (i.e. clinical symp-
toms and functioning) and personal subjective including
in particular QoL among other domains such as personal
confidence and hope, willingness to ask for help [37,38].
Our findings suggest that personal subjective recovery
(i.e. QoL in our study) is more predictive of relapse than
objective recovery. These findings should however be con-
firmed on other domains of subjective recovery. On the
other hand, these results should be considered to improve
the characterisation and treatment of patients with schizo-
phrenia. Our findings may support the development and
monitoring of complementary therapeutic approaches,
such as ‘recovery-oriented’ combined with traditional
mental health cares to prevent relapse. Interestingly, QoL
has been linked to metacognitive capacities in recent stud-
ies [39,40], suggesting that interventions targeting meta-
cognition, such as psychotherapy, may play a key role in
preventing relapse [41].
Limitations
Some limitations of this study have to be carefully
considered.
First, a problem remains with the definition of relapse
for schizophrenic patients. There are no consensual cri-
teria for relapse [30]. Admission to a psychiatric hospital
unit, increase in medication, worsening of florid symp-
toms of schizophrenia, worsening of any psychiatric symp-
toms, and threatened clinical exacerbations have all been
variables used to indicate relapse [42]. However, in this
study, we have chosen the most commonly used definition
in the recent scientific literature.
Second, the representativeness of our sample should
be discussed. Although the sampling procedure for the
EuroSC aimed to provide a representative sample of the
patients treated, this cohort of patients had mostly para-
noid schizophrenia and was characterized by long-term
illness [20]. Moreover, excluded patients presented with
a higher clinical severity than included patients. Replica-
tion is therefore needed, using larger and more diverse
groups of patients.
Third, 43% is a moderately high attrition rate in our
study at 24 months, and this can lead to biased esti-
mates, especially if patients who did not follow up failed
to do so because they suffered a higher relapse rate due
to higher clinical severity. However, three facts suggest
minimal bias due to attrition. First, among patients lost
to follow up, 40.3% had a relapse before their last visit
and were thus included in the analysis. Second, patients
lost to follow up did not differ significantly in age, gen-
der, or PANSS scores at baseline from those patients
who did follow up (p > 0.05; data not shown). Third, the
relapse rate was relatively high (53%), suggesting thatrelapses were globally detected. Finally, attrition and
relapse rates were globally within the range of other
schizophrenia cohorts [1,5,6,43].
Fourth, the SF36 is a generic measure and may not
adequately capture all areas of functioning and well-being
that are relevant to people with schizophrenia [44]. More-
over, a recent review raised question about metrological
properties of the SF36 in schizophrenia [45]. Future inves-
tigators should attempt to replicate our findings using
disease-specific instruments.
Fifth, compliance is not easy to detect and quantify, and
all methods of detection have some drawbacks. As such,
the use of the ROMI may be criticised. This scale is a
subjective method of assessing compliance in comparison
with objective methods such as pill counts, pharmacy
records, electronic monitor and plasma concentrations.
However, as suggested by Velligan et al., even the use of
more objective measures can result in significant errors
[46]. Moreover, the ROMI has several advantages. It has
good psychometric properties and predicts compliance
satisfactorily [27].
Sixth, although our models account for a large set of
potentially relevant variables, other factors might have
increased their explanatory power. For example, having
a history of previous relapse or hospitalisation was not a
variable that we examined in our study, although it has
previously been identified as an important predictor of
relapse [1]. However, in the present study, patients did
not have any relapse or hospitalisation for the 12 months
prior to the baseline evaluation in accordance with the
inclusion criteria. Lastly, despite our large sample, this
study only included 3 European countries. Given the im-
portant influence of cultural, social, and environmental
context on QoL, it would be necessary to know whether
our findings can be replicated in other countries.
Conclusion
This study shows that QoL measures can be considered as
an independent predictor of relapse in schizophrenia. This
finding may have implications for the future use of QoL in
psychiatry. To date, QoL remains largely under-utilized in
clinical practice [47]. Several studies have reported that
clinicians believe that QoL measures lack clinical rele-
vance for their patients [48,49]. More work must be done
to convince clinicians of the clinical relevance of QoL
instruments in order to enhance the use of QoL measures
in clinical decision-making [50]. Our findings, similar to
those in other studies, especially in oncology, provide
strong support for the integration of QoL into clinical
practice along with other standard assessments in
psychiatry.
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